Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18–75, and have confirmed stomach or gastroesophageal junction (GEJ) cancer
- Have had curative stomach surgery with D2 lymph node removal and no/limited remaining tumor (R0 or R1)
- Have stage III cancer (8th AJCC) and currently have no detectable cancer on scans in the last 28 days
- Be able to do daily activities fairly well (ECOG 0–1) and have life expectancy >6 months
- Have recent blood tests within required ranges for bone marrow, liver, and kidney function
- Not have recent major bleeding, brain metastases, uncontrolled heart problems, blood clots in the last 6 months, or the need for corticosteroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This study tests a new way to guide treatment after surgery for stomach cancer. It uses a blood test to look for tiny pieces of cancer DNA, and then gives extra treatment only to people who still have signs of cancer. The goal is to prevent the cancer from coming back.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.